Amgen (AMGN): No Conclusion on Sensipar's Role in Death, Still Working with FDA

Article Related Articles (2) Stock Quotes (1) Comments (0)

Amgen, Inc. (NASDAQ: AMGN) says there is no conclusion on Sensipar's role in death outlined by the FDA. The company said it was still working with the FDA on Sensipar development.

Comments were made by a spokesperson via email to Bloomberg.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Yahoo! (YHOO) Board Said to Approve $1.1B Tumblr Deal
• Apple (AAPL) Continues Higher
• Dell (DELL) Special Committee Sends Letter to Icahn, Southeastern

Create E-mail Alert Related Categories

Corporate News, FDA, Insiders' Blog

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?